1051372-09-8

Basic information

• Product Name: 3-BROMO-5-NITRO-2-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE
• Synonyms: 3-BROMO-5-NITRO-2-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE
• CAS NO: 1051372-09-8
• Molecular Formula: C₇H₄BrF₃N₂O₃
• Molecular Weight: 301.03
• Mol File: 1051372-09-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BROMO-5-NITRO-2-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-NITRO-2-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE(1051372-09-8)
• EPA Substance Registry System: 3-BROMO-5-NITRO-2-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE(1051372-09-8)

Safety Data

• Hazardous Substances Data: 1051372-09-8(Hazardous Substances Data)

Usage

Uses

3-Bromo-5-nitro-2-(2,2,2-trifluoro-ethoxy)-pyridine is used as a reactant in the preparation of N-arylamide oxadiazoles as selective oral CB2 agonists.

Upstream product

• 5470-17-7 3-bromo-2-chloro-5-nitropyridine 
• 75-89-8 2,2,2-trifluoroethanol 

Downstream Products

• 1372606-89-7 5-(4-chloro-phenyl)-6-(2, 2, 2-trifluoro-ethoxy)-pyridin-3-ylamine 
• 1372605-60-1 N-(5-(4-chloro-3-methylphenyl)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-nicotinamide 
• 1372605-58-7 N-(5-(3,4-dimethylphenyl)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-nicotinamide 
• 1372604-76-6 pentanoic acid[5-(4-chloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-pyridin-3-yl]-amide 
• 1372606-85-3 5-bromo-6-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylamine 

Relevant articles and documents

N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES

The present invention relates to compounds of the formula wherein R1 to R3 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES

The present invention relates to compounds of formula I, wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof. The present invention also relates to the manufacture of such compounds or

Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB 2) agonists

The CB2 receptor is an attractive therapeutic target for analgesic and anti-inflammatory agents. Herein we describe the discovery of a novel class of oxadiazole derivatives from which potent and selective CB 2 agonist leads were developed. Initial hit 7 was identified from a cannabinoid target-biased library generated by virtual screening of sample collections using a pharmacophore model in combination with a series of physicochemical filters. 7 was demonstrated to be a selective CB2 agonist (CB2 EC50 = 93 nM, Emax = 98%, CB 1 EC50 > 10 μM). However, this compound exhibited poor solubility and relatively high clearance in rat, resulting in low oral bioavailability. In this paper, we report detailed SAR studies on 7 en route toward improving potency, physicochemical properties, and solubility. This effort resulted in identification of 63 that is a potent and selective agonist at CB2 (EC50 = 2 nM, Emax = 110%) with excellent pharmacokinetic properties.